Vivacelle Bio, Inc. - VBI
VBI has an IV phospholipid nanoparticle based fluid for hypovolemic shock. Est. $13 billion market, quick FDA pathway. Patents. Can relocate.
Vivacelle Bio, has developed VBI-1, a phospholipid nanoparticle injectable to sustain life after severe injury causing hypovolemic shock. Competing products have toxicity and are more expensive. The formulation is based on non-toxic FDA-approved products that qualifies VBI-1 for an expedited FDA pathway. Preclinical studies show safety efficacy and protection from reperfusion injury. Experienced management. $13 billion addressable market.